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Abstract
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We have used a novel microwave-assisted method developed in our laboratories to synthesize a
series of ruthenium-thiosemicarbazone complexes. The new thiosemicarbazone ligands are
derived from benzo[d][1,3]dioxole-5-carbaldehyde (piperonal) and the complexes are formulated
as [(diimine)2Ru(TSC)](PF6)2 (where the TSC is the bidentate thiosemicarbazone ligand). The
diimine in the complexes is either 2,2'-bipyridine or 1,10-phenanthroline. The complexes have
been characterized by spectroscopic means (NMR, IR and UV-Vis) as well as by elemental
analysis. We have studied the biophysical characteristics of the complexes by investigating their
anti-oxidant ability as well as their ability to disrupt the function of the human topoisomerase II
enzyme. The complexes are moderately strong binders of DNA with binding constants of 104
M−1. They are also strong binders of human serum albumin having binding constants on the order
of 104 M−1. The complexes show good in vitro anticancer activity against human colon cancer
cells, Caco-2 and HCT-116 and indeed show some cytotoxic selectivity for cancer cells. The IC50
values range from 7 – 159 μM (after 72 h drug incubation). They also have antibacterial activity
against Gram-positive strains of pathogenic bacteria with IC50 values as low as 10 μM; little
activity was seen against Gram-negative strains. It has been established that all the compounds are
catalytic inhibitors of human topoisomerase II.

Keywords
Thiosemicarbazone; diimine; DNA; anticancer; human serum albumin; topoisomerase II

© 2011 Elsevier B.V. All rights reserved
*
floyd.beckford@lyon.edu, Ph: (870) 307-7212; Fax: (870) 307-7496.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Beckford et al.

Page 2

1 Introduction
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Schiff bases are an important set of chelatin ligands in main group and transition metal
coordination chemistry and have become an important class of compounds in medicinal and
pharmaceutical fields as well [1–3]. Metal complexes of Schiff bases have been designed
and synthesized to explore their pharmacological activity, for instance finding applications
as model analogues of certain metallo-enzymes. One particular set of Schiff bases that has
been studied very aggressively over the past decade is the thiosemicarbazones.
Thiosemicarbazones are of considerable pharmacological interest since a number of
derivatives have shown a broad spectrum of chemotherapeutic properties. The wide range of
biological activities possessed by substituted thiosemicarbazones includes cytotoxic,
antitumor [4], antibacterial [5], and antiviral [6] properties. The biological properties of the
ligands can be modified and enhanced by linkage to metal ions [7–9].
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Ruthenium complexes of diimine ligands such as 2,2′-bipyridine (bpy) and 1,10phenanthroline (phen) are widely used in bioinorganic chemistry particularly as probes for
DNA. Some of these compounds also possess interesting anticancer properties and may be
candidates for drugs [10–15]. While it is believed that DNA is a primary target for such
complexes, since DNA replication is integral to the progression of these diseases, there is
also the recognition that the observed biological activity is not always related to their DNAbinding ability. Consequently studies that seek to investigate other possible targets such as
enzymes and other proteins are being undertaken [16–18]. The binding of drugs to plasma
proteins is a fundamental factor, important in determining the overall pharmacological
activity of the drug. Among the human serum proteins, albumin (HSA) acts as a reservoir
for a long duration of action, and binding ultimately affects drug absorption, metabolism,
distribution and excretion, properties that are of key importance to drug development. Since
HSA serves as a transport carrier for drugs, it is important to study the interactions of
potential drugs with this protein.
In this paper we report on a study of a family of mixed-ligand diimine ruthenium complexes
of the type [(bipy)2Ru(TSC)](PF6)2 and [(phen)2Ru(TSC)](PF6)2 where TSC is a chelating
thiosemicarbazone ligand derived from piperonal. We report on their biophysical reactivity
(-interaction with DNA and human serum albumin), their cytotoxicity towards a number of
human cancer cell lines and their antibacterial behavior towards a number of pathogenic and
facultative bacteria. We also report their capability as antioxidants by investigating their
reactivity with 2,2-diphenyl-1-picrylhydrazyl (dpph) radicals.

2. Experimental Section
NIH-PA Author Manuscript

2.1 Materials and methods
Analytical or reagent grade chemicals were used throughout. All the chemicals including
solvents were obtained from Sigma-Aldrich (St. Louis, MO, USA) or other commercial
vendors and used as received. The metal complexes were synthesized using a Discover SClass microwave reactor (CEM, Matthews, USA). Microanalyses (C, H, N) were performed
by Desert Analytics, Tucson, USA. Proton and carbon nuclear magnetic resonance (NMR)
spectra were recorded in dimethylsulfoxide-d6 on a Varian Mercury 300 MHz spectrometer
operating at room temperature. The residual 1H and 13C present in DMSO-d6 (2.50 and
39.51 ppm respectively) were used as internal references. Infrared (IR) spectra in the range
4000 – 500 cm−1 were obtained using the ATR accessory on a Nicolet 6700 FTIR
spectrophotometer. The electronic spectra were recorded using quartz cuvettes on an Agilent
8453 spectrophotometer in the range 190 – 1100 nm using samples dissolved in DMSO.
Fluorescence spectra were recorded on a Varian Cary Eclipse spectrophotometer.
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2.1.1 Synthesis of compounds
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2.1.1.1 Ligands: The ligands, 2-(benzo[d][1,3]dioxol-5ylmethylene)hydrazinecarbothioamide, (HpTSC), 2-(benzo[d][1,3]dioxol-5-ylmethylene)-Nmethylhydrazinecarbothioamide, (MepTSC), 2-(benzo[d][1,3]dioxol-5-ylmethylene)-Nethylhydrazinecarbothioamide, (EtpTSC) and 2-(benzo[d][1,3]dioxol-5-ylmethylene)-Nphenylhydrazinecarbothioamide (PhpTSC), were synthesized as follows: Equimolar
amounts piperonal (benzo[d][1,3]dioxole-5-carbaldehyde) and the appropriate N(4) alkylsubstituted thiosemicarbazide were suspended in 80 mL of absolute anhydrous ethanol
containing a few drops of glacial acetic acid. The reaction mixture was heated at reflux for
3–4 h and a pale yellow suspension resulted. The reaction mixture was cooled and filtered
through a glass-sintered crucible. The pale yellow solid which was obtained was thoroughly
washed with ethanol followed by ether and dried by suction.
pHTSC: Yield 80% of an off-white solid. Analysis - Calc for C9H9N3O2S: C, 48.42; H,
4.06; N, 18.82. Found: C, 48.40; H, 4.02; N, 18.67. m.p.189 °C. IR (cm−1): ν (NH2, NH)
3427, 3252, 3153; ν (C=N) 1592; ν (C=S) 1260, 838. 1H NMR (300.08 MHz, DMSO-d6): δ
= 6.04 (2H, s, H1), 7.63 (1H, s, H3), 7.04 (1H, d J = 8.4 Hz, H5), 6.89 (1H, d J = 7.8 Hz,
H6), 7.92 (1H, s, H8), 8.01 (1H, s, NbH), 8.04 (1H, s, NbH), 11.3 (1H, s, NaH). 13C NMR
(75.463 MHz, DMSO-d6); δ = 102.01 (C1), 105.97 (C6), 108.81 (C3), 124.55 (C5), 129.42
(C4), 142.68 (C8), 148.70 (C2), 149.54 (C7), 178.30 (C9).
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pMeTSC: Yield 96% of a pale-yellow solid. Analysis - Calc for C10H11N3O2S: C, 50.62; H,
4.67; N, 17.71. Found: C, 50.62; H, 4.62; N, 17.50. m.p. 209 °C. IR (cm−1): ν (NH2, NH)
3344, 3152; ν (C=N) 1590; ν (C=S) 1283, 828. 1H NMR (300.08 MHz, DMSO-d6): δ = 6.07
(2H, s, H1), 7.66 (1H, s, H3), 7.07 (1H, d J = 8.1 Hz, H5), 6.91 (1H, d J = 7.8 Hz, H6), 8.51
(1H, s, H8), 7.94 (1H, s, NbH), 11.38 (1H, s, NaH), 3.00 (3H, t, Nb-CH3). 13C NMR (75.463
MHz, DMSO-d6); δ = 30.78 (Nb-CH3), 101.47 (C1), 105.15 (C6), 108.19 (C3), 123.76 (C5),
128.88 (C4), 141.38 (C8), 148.82 (C2), 148.06 (C7), 177.51 (C9).
pEtTSC: Yield 84% of a pale-yellow solid. Analysis - Calc for C11H13N3O2S: C, 52.57; H,
5.21; N, 16.72. Found: C, 52.66; H, 5.06; N, 16.58. m.p. 169 °C. IR (cm−1): ν (NH2, NH)
3375, 3143; ν (C=N) 1589; ν (C=S) 1255, 832. 1H NMR (300.08 MHz, DMSO-d6): δ = 6.07
(2H, s, H1), 7.66 (1H, s, H3), 7.07 (1H, d J = 8.1 Hz, H5), 6.92 (1H, d J = 7.8 Hz, H6), 8.56
(1H, s, H8), 7.94 (1H, s, NbH), 11.32 (1H, s, NaH), 3.58 (2H, q, Nb-CH2), 1.14 (3H, t, NbCH2-CH3). 13C NMR (75.463 MHz, DMSO-d6); δ = 14.72 (Nb-CH2-CH3), 38.22 (Nb-CH2CH3), 101.47 (C1), 105.23 (C6), 108.19 (C3), 123.78 (C5), 128.84 (C4), 141.50 (C8),
148.83 (C2), 148.05 (C7), 176.46 (C9).
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pPhTSC: Yield 94% of a light-yellow solid. Analysis - Calc for C15H13N3O2S: C, 60.18; H,
4.38; N, 14.04. Found: C, 60.21; H, 4.50; N, 13.95. m.p. 189 °C. IR (cm−1): ν (NH2, NH)
3353, 3134; ν (C=N) 1597; ν (C=S) 1253, 869. 1H NMR (300.08 MHz, DMSO-d6): δ = 6.08
(2H, s, H1), 7.85 (1H, s, H3), 7.55 (1H, d J = 14 Hz, H5), 7.38 (1H, d J = 15 Hz, H6), 8.07
(1H, s, H8), 10.11 (1H, s, NbH), 11.74 (1H, s, NaH), 6.93 – 7.25 (5H, m, Nb-C6H5). 13C
NMR (75.463 MHz, DMSO-d6); δ = 101.50 (C1), 105.67 (C6), 108.18 (C3), 142.67 (C8),
149.09 (C2), 148.10 (C7), 175.78 (C9). The phenyl carbons were located in a closely-spaced
cluster between 120 –130 ppm that overlapped with the signals from the aromatic ring of the
benzodioxole moiety.
2.1.1.2 Metal complexes: The starting ruthenium complexes, [(phen)2RuCl2]·H2O and
[(bpy)2RuCl2], were synthesized as described in the literature [19]. The target complexes
were synthesized by the following general method: Equimolar amounts of [(phen)2RuCl2]
·H2O or [(bpy)2RuCl2] and the appropriate ligand was suspended in 8 – 10 mL of ethylene
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glycol in a 35-mL reaction vessel. The vessel was capped and the reaction mixture saturated
with argon for 15 minutes. The reaction vessel was then placed in the microwave reactor and
heated at 150 °C for 5 minutes (using a dynamic method). The dark brown suspension
became a dark red solution. This solution was poured onto 5 – 10 mL of a saturated aqueous
solution of KPF6 which resulted in the immediate precipitation of a red solid. The solid was
collected by vacuum filtration, washed with water followed by ether and then dried at the
vacuum pump. The product was recrystallized from dichloromethane/ether (1 and 2),
ethanol/hexanes (3 and 4) or ethanol/ether (5).
[(bpy)2Ru(HpTSC)](PF6)2: 1. Red solid. Yield: 180 mg (47%). Analysis; Calc. for
C29H25F12N7O2P2Ru S: C, 37.59; H, 2.72; N, 10.58. Found: C, 37.84: H, 2.73; N, 10.75. IR
(cm−1): ν (NH2, NH) 3424(w), 3373, 3152(w); ν (C=N) 1620; ν (N-N) 1036; ν (C=S) 1255,
830; λmax (log ε); 294 nm (3.8); 430 nm (broad).
[(bpy)2Ru(EtpTSC)](PF6)2: 2. Red solid. Yield: 259 mg (66%). Analysis; Calc. for
C31H29F12N7O2P2Ru S: C, 39.00; H, 3.06; N, 10.26. Found: C, 39.29; H, 3.18; N, 10.18. IR
(cm−1): ν (NH2, NH) 3421(w), 3113(w, b); ν (C=N) 1586; ν (N-N) 1034; ν (C=S) 1247,
827; λmax (log ε); 303 nm (3.8); 276 nm (broad).
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[(phen)2Ru(HpTSC)](PF6)2·0.25C4H10O: 3. Red solid. Yield: 166 mg (47%). Analysis;
Calc. for C34H27.5F12N7O2.5P2Ru S: C, 41.12; H, 2.79; N, 9.87. Found: C, 41.84; H, 2.42;
N, 10.33. IR (cm−1): ν (NH2, NH) 3424, 3373(w), 3152(w); ν (C=N) 1620; ν (N-N) 1036; ν
(C=S) 1251, 830; λmax (log ε); 300 nm (sh); 430 nm (broad).
[(phen)2Ru(MepTSC)](PF6)2: 4. Dark-red solid. Yield: 256 mg (71%). Analysis; Calc. for
C34H27F12N7 O2P2Ru S: C, 41.30; H, 2.75; N, 9.92. Found: C, 42.20; H, 2.62; N, 10.19. IR
(cm−1: ν (NH2, NH) 3424(w), 3337(w); ν (C=N) 1620; ν (N-N) 1036; ν (C=S) 1256, 833;
λmax (log ε); 360 nm (sh); 440 nm (broad).
[(phen)2Ru(EtpTSC)](PF6)2: 5. Dark-red solid. Yield: 286 mg (71%). Analysis; Calc. for
C35H29F12N7 O2P2Ru S: C, 41.92; H, 2.92; N, 9.78. Found: C, 41.80; H, 2.68; N, 9.88. IR
(cm−1: ν (NH2, NH) 3420, 3371(w); ν (C=N) 1574; ν (N-N) 1036; ν (C=S) 826; λmax (log
ε); 292 nm (3.8); 400 nm (broad).
2.2 DNA-interaction studies
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All experiments involving interaction of the complexes with DNA were carried out in Tris
buffer (5 mM Tris, 50 mM NaCl, pH 7.20). Stock solutions of ct-DNA were prepared by
dissolving commercial nucleic acids in buffer and stored at 4 °C for more than 24 h to
achieve homogeneity. After dilutions DNA concentration per nucleotide phosphate was
determined spectrophotometrically using the molar absorption coefficient of 6600 M−1 cm−1
at 260 nm [20]. A solution of ct-DNA in the buffer gave a ratio of UV absorbance at 260
and 280 nm of ≥ 1.8 indicating that the DNA did not require purification [21]. The DNA
stock solutions were stored at −20 °C and used within 1 week after their preparation. The
doubly purified water used in all experiment was from a Milli-Q system.
2.2.1 Viscosity measurements—Viscosity studies were carried out using a CannonManning semi micro-dilution viscometer (type 75, Cannon Instruments Co., State College,
PA, USA) immersed vertically in a thermostatted water bath maintained at 31 ± 1 °C. The
viscosity of DNA solutions was measured in the presence and absence of the metal
complexes. The DNA concentration was maintained at 10 μM, while the complex
concentration varied from 0 – 60 μM. Data are presented as (η/η0)1/3 versus 1/R, where R =
[DNA]/[complex] and η is the viscosity of DNA in the presence of the complex and η0 is the
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relative viscosity of DNA alone. Relative viscosity values were calculated from the observed
flow times of DNA solution (t) corrected for the flow time of buffer alone (t0), using the
expression η0 = (t − t0)/t0. Flow time was measured with a digital stopwatch and each
sample was measured three times and the average flow time was used.
2.2.2 Ethidium bromide displacement experiments—In the ethidium bromide (EB)
displacement experiment, a 3-mL sample of a solution that was 10 μM DNA and 0.33 μM
EB (saturated binding levels [22]), in Tris buffer was titrated with aliquots of a concentrated
solution of a complex producing reaction mixtures with varied mole ratio of complex to ctDNA. After each addition the solution was vortex for 30 seconds and allowed to mix at the
appropriate temperature for 5 minutes before measurement. The fluorescence spectrum of
the solution was obtained by exciting at 520 nm and measuring the emission spectra from
540 – 700 nm using 5 nm slits.
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2.2.3 Chemical nuclease activity—The DNA unwinding and cleavage ability of the
complexes were evaluated by agarose gel electrophoresis of supercoiled pBR322 DNA. The
experiments were done in the dark or after exposure to long-radiation UV light. Samples of
pBR322 DNA (0.1 μg/μL) were incubated with the complexes (in concentrations ranging
from 10 to 300 μM) in Tris buffer (50 mM Tris, 18 mM NaCl, pH 8.2) at room temperature
for 1 h in the dark or subjected to 365 nm light. The reactions were quenched by addition of
3 μL of loading buffer (0.25% bromophenol blue and 15% Ficoll in water). Samples of the
reaction mixtures were loaded onto a 1% agarose gel in TBE buffer (89 mM Tris, 89 mM
boric acid, 2 mM EDTA, pH 8.2). The gels were subjected to electrophoresis for 1 h at 70 V,
followed by staining with 0.5 μg/mL ethidium bromide for 30 minutes. The bands on the gel
were visualized under UV light and photographed using a GEL Logic 440 Imaging System
with a Kodak Molecular Imaging Software.
2.3 Activity against topoisomerase II
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The capability of the ruthenium complexes to affect human topoisomerase II activity was
analyzed using gel electrophoresis. The reaction mixture was a total of 20 μL and Tris buffer
(50 mM Tris, 18 mM NaCl, pH 7.2) was used as the reaction buffer for the complexes. The
“complete buffer” was made fresh daily by adding equal volumes of 10× Topo II Assay
Buffer A (0.5 M Tris-HCl (pH 8), 1.50 M NaCl, 100 mM MgCl2, 5 mM dithiothreitol and
300 μg BSA/mL) to the 10× ATP Buffer B (20 mM ATP in water) and was used at 1/5
volume. The metal complexes were added from a 3 mM stock solution made fresh in a 1:1
solution of DMSO and Tris buffer to yield varying concentrations (20 μM, 50 μM, 100 μM,
and 300 μM). Etoposide used as a control poison was added from a 10 mM stock solution in
DMSO to create a 1 mM concentration in the reaction. Also a control lane, in which DMSO
was added to DNA at the highest concentration it appears in a single reaction, was included.
DNA (pHOT-1) was used at a concentration of 12.5 ng/μl. Human topoisomerase IIα (3
units, 1.5 μl) was added and the reactions were immediately transferred from the ice bath to
a 37 °C hot water bath for 30 minutes. The reactions were terminated by adding 1/10 volume
of 10% sodium dodecyl sulfate. Proteinase K was added at a concentration of 50 μg/ml. The
reactions were incubated in the hot water bath for an additional 15 minutes. 1/10 volume of
10× gel loading buffer was added and the reactions removed from the water bath. They were
cleaned up via a CIA extraction. An equal volume of CIA (chloroform:isoamyl alcohol
24:1) was added, the mixture vortex and then briefly centrifuged. The upper blue layer was
split in half and placed into corresponding wells of two 1% agarose gels in Tris-BorateEDTA buffer (TBE). The gels were run at 70 V for 2 h in TBE. One gel contained 0.2 μg/ml
ethidium bromide. This EB gel was run with TBE containing 0.5 μg/ml ethidium bromide.
This gel was then de-stained in DNA-free water for 30 minutes while the other gel was
stained in an ethidium bromide/buffer solution for 30 minutes. It was then de-stained as
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mentioned before. The bands on the gel were imaged under UV light using a GEL Logic 440
Imaging System with Kodak Molecular Imaging Software.
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2.4 DPPH antioxidant assay
The assay was conducted in a 96-well plate with a total volume of 250 μL in each well. To
various concentrations of the metal complex DPPH was added (to a final concentration of
150 μM) and the reactions incubated at 25 °C for 30 minutes in the dark (shielded from
light) before the absorbances were read at 520 nm. Ascorbic acid (AA) was used as a
comparison and a reagent blank along with a control were included on the plate. The control
is a solution of DPPH and the reagent blank is a solution of the complex at the appropriate
concentrations.

SC% is the scavenging capacity. IC50 values denote the concentration of metal complex
required to scavenge 50% of the DPPH radicals and were obtained from a plot of SC vs.
[metal complex]. Acontrol is the absorbance of the control and Asample is the absorbance of
the sample.
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2.5 Reaction with human serum albumin (HSA)
For the fluorescence titration, a similar procedure to the EB displacement experiments was
done. Solutions of HSA (fatty acid-free) were prepared in Tris buffer (50 mM Tris, pH 7.40,
100 mM NaCl) and stored in the dark at 4 °C. The protein concentration was determined
spectrophotometrically using the molar absorptivity of 36 000 M−1 cm−1 at 280 nm [23]. In
the experiments, a 3.0-mL solution of HSA (5 μM) was placed in a quartz cuvette and
titrated with various amounts of a concentrated solution of the complex producing solutions
with varied mole ratios of complex to HSA. The complex concentration ranged from 3 – 30
μM. The fluorescence spectra of the solutions were obtained by exciting at 295 nm and
measuring the emission spectra from 300 – 500 nm.
2.6 Cell culture
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Cell lines included two human colon cancer cells: HCT-116 (human colon carcinoma) and
Caco-2 (human epithelial colorectal adenocarcinoma). In addition, normal human colon
cells CCD-18Co (human colon fibroblasts) were included. All cell lines were obtained from
the American Type Culture Collection (ATCC, Rockville, MD, USA) and maintained at the
University of Rhode Island. Caco-2 cells were grown in EMEM medium supplemented with
10% v/v fetal bovine serum, 1% v/v nonessential amino acids, 1% v/v L-glutamine and 1%
v/v antibiotic solution (Sigma). HCT-116 cells were grown in McCoy's 5a medium
supplemented with 10% v/v fetal bovine serum, 1% v/v nonessential amino acids, 2% v/v
HEPES and 1% v/v antibiotic solution. CCD-18Co cells were grown in EMEM medium
supplemented with 10% v/v fetal bovine serum, 1% v/v nonessential amino acids, 1% v/v Lglutamine and 1% v/v antibiotic solution and were used from PDL = 26 to PDL = 35 for all
experiments. Cells were maintained at 37 °C in an incubator under a 5% CO2/95% air
atmosphere at constant humidity and maintained in the linear phase of growth. The pH of
the culture medium was determined using pH indicator paper (pHydrion™ Brilliant, pH 5.5–
9.0, Micro Essential Laboratory, NY, USA) inside the incubator. All of the test samples
were solubilized in DMSO (<0.5 % in the culture medium) by sonication and were filter
sterilized (0.2 μm) prior to addition to the culture media. Control cells were also run in
parallel and subjected to the same changes in medium with a 0.5 % DMSO.
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2.6.1 Cytotoxicity assay—The assay was carried out as described previously [24] to
measure the IC50 values for samples. Briefly, the in vitro cytotoxicity of samples were
assessed in tumor cells by a tetrazolium-based colorimetric assay, which takes advantage of
the metabolic conversion of MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfenyl)-2H-tetrazolium, inner salt] to a reduced form that
absorbs light at 490 nm. Cells were counted using a hemacytometer and were plated at 2,000
– 5,000 cells per well, depending on the cell line, in a 96-well format for 24 h prior to drug
addition. Test samples and a positive control, etoposide (4 mg/mL), were solubilized in
DMSO by sonication. All samples were diluted with media to the desired treatment
concentration and the final DMSO concentration per well did not exceed 0.5%. Control
wells were also included on all plates. Following a 24 h, 48 h or 72 h drug-incubation period
at 37 °C with serially diluted test compounds, MTS, in combination with the electron
coupling agent, phenazine methosulfate, was added to the wells and cells were incubated at
37°C in a humidified incubator for 3 h. Absorbance at 490 nm (OD490) was monitored with
a spectrophotometer (SpectraMax M2, Molecular Devices Corp., operated by SoftmaxPro v.
4.6 software, Sunnyvale, CA, USA) to obtain the number of surviving cells relative to
control populations. The results are expressed as the median cytotoxic concentrations (IC50
values) and were calculated from six-point dose response curves using 4-fold serial
dilutions. Each point on the curve was tested in triplicate. Data are expressed as mean ± SE
for three replicates on each cell line.
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2.7 Antimicrobial assay
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The in vitro antimicrobial activity of the complexes was investigated as the minimum
inhibitory concentration (MIC) against a number of Gram-positive (Staphylococcus aureus,
Bacillus cereus, Enterococcus faecalis) and Gram-negative (Escherichia coli, Pseudomonas
aeruginosa, Salmonella typhimurium) bacteria strains. The bacteria were maintained on
nutrient agar and cultured in Mueller Hinton Broth and compounds were dissolved in
DMSO. The MIC was determined from a microdilution method. Approximately 30 mL of
bacteria culture were incubated overnight at 37.0 °C to produce exponentially growing cells.
This was then diluted to yield a suspension containing 1.5 × 108 CFU/mL (based on
comparison of the turbidity to a 0.5 McFarland standard). Subsequently, 250 μL of this
bacteria mixture were inoculated into a sterile 96-well microplate. Various amounts of the
compounds were added to wells to give predetermined concentrations ranging from 2 – 50
μM. The well absorbances (at 600 nm) were recorded on a BioTek Synergy HT microplate
reader immediately after inoculation. The microplates were incubated for 24 h at 37.0 °C,
and then the absorbance recorded again after the 24 h period. The MIC was defined as the
lowest concentration of compound that did not produce any visible cell-growth or change in
absorbance after incubation. Solvent, media and positive growth controls were included on
each plate. Ampicillin or streptomycin was used as a standard comparison. Each plate
contained three replicates of each concentration and two separate experiments were done.

3 Results and Discussion
The ligands were synthesized using a general method involving the acid-catalyzed
condensation of piperonal with the corresponding N-alkyl substituted thiosemicarbazide in
ethanol. The complexes were made using a microwave-assisted thermal reaction of the
dichlorobis(diimine)ruthenium(II) starting material with the ligands. [Ru(diimine)2Cl2] and
ligand were suspended in the ethylene glycol solvent and the reaction mixture saturated with
argon. The mixture was then heated using a dynamic method that was developed as follows:
time = 5 min; temperature = 150 °C; power = variable; stirring = max; cooling = on. The
reaction produced red solids that are insoluble in alcohols and water but are very soluble in
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acetone, CH2Cl2 and DMSO. From microanalytical and spectroscopic data we propose that
the complexes can be formulated as [(diimine)2Ru(TSC)](PF6)2 (Fig. 1).
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3.1 Nuclear magnetic resonance
A simple comparison of the NMR spectra of the ligands and the metal complexes reveals the
presence of the azomethinic proton signal in the spectra of the complexes which is indicative
of the non-deprotonation of the ligand confirming the neutrality of the coordinated
thiosemicarbazone. In all the complexes there is a general upfield shift of nearly 1 – 1.5
ppm, which reflects coordination through the azomethine nitrogen. We have previously
noted this behavior for similar complexes [25]. The signal ascribed to the aminic proton in
the free ligands along with that for the aldehydic proton is buried under the multiplet of
peaks between 6 and 9 ppm that is associated with the diimine group but we have seen for
similar complexes that the aminic proton generally move downfield by as much as 0.5 ppm.
This is indicative of the binding of the thiocarbonyl group and is the result of a decrease in
the electron density caused by electron withdrawal by the metal ions from the thione sulfur.
The protons associated with the 1,3-dioxole fragment do not shift and show up at
approximately 6.00 ppm for all the complexes. The other proton signals show up at their
expected positions.
3.2 Infrared spectra
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Thiosemicarbazones exhibit characteristic bands corresponding to various functional groups
in specific energy regions. Thiosemicarbazone ligands can coordinate in a number of
different ways. Most commonly they bind as either of two tautomeric forms – a neutral
thione form or the anion from the thiol form. Infrared spectrophotometry can be used to
identify the coordinated form and it was observed that the characteristic absorption peaks of
all complexes are similar. The absence of a n(S–H) absorption in the region 2600–2500
cm−1 is considered as evidence that the thione form of the ligands exist in the solid state
[26,27]. There are two or three weak and broad bands in the n(N–H) region (3450 – 3150
cm−1) and these signals play an important role in evaluating the nature of the bonding in
thiosemicarbazone complexes. The presence of these bands supports the thione formulation
of the ligand in the complexes and they do not shift significantly on complexation. The
coordination sites can also be inferred from the spectral bands attributed to the C=N iminic
and C=S thioamide IV groups. The ligands show a medium intensity band at 1570 – 1620
cm−1 that we ascribe to C=N and these are shifted slightly to higher or lower energy upon
complexation. The bands in the free ligand attributed to the C=S group shifts to lower
frequencies by 4 – 27 cm−1. The size of the shifts suggest that the ligand coordinates as a
neutral, bidentate (through the azomethine nitrogen and thiocarbonyl sulfur) ligand in all the
complexes. The presence of the azomethinic hydrogen in all the complexes indicates the
lack of thiolate formation.
3.3 Interaction with DNA
3.3.1 Ethidium bromide competition experiment—The complexes do not have a
peak with strong enough absorption spectrophotometry. So we have investigated the
reaction of the complexes with calf thymus DNA via a fluorescence competition experiment.
Ethidium bromide (EB) is a well-known dye that is commonly used as a marker for nucleic
acids by intercalating between the base pairs and generating a fluorescent adduct. The
fluorescence from the adduct may be quenched by addition of a compound that can displace
the EB from the binding sites on the DNA [25]. This quenching may be taken as evidence
that the compound can bind to DNA likely in a similar fashion to EB. Using 2 as a typical
example, (also see Supplemental Information - S1), we can see from Figure 2 that the
complex can indeed reduce the fluorescence of the EB-DNA solution. A quantitative
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estimate of this quenching behavior may be obtained by treating the data according to the
Stern-Volmer equation (1):
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(1)

In this equation F0 and F are the fluorescence intensities of the reaction solution in the
absence and presence of the metal compound. KSV is the Stern-Volmer quenching constant
which is the measure of the effectiveness of the complex as a quencher. Figure 3 shows the
Stern-Volmer plots and the excellent linearity of the plots confirms the quenching behavior.
The values of the quenching constant, seen in Table 1, range from 1.6 × 104 to 4 × 104 M−1
indicating that these are only moderate quenchers. In general, the complexes with the phen
unit are stronger quenchers than the bpy complexes. This might implicate an intercalative
mode (albeit weak) of binding. To assess the strength of the binding, equation 2 was
employed to calculate the apparent binding constant.

(2)
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The quenching of the fluorescence can occur by two common mechanisms – dynamic and/or
static quenching. We propose that in the reactions here the quenching is predominantly
static. In such a scenario a quencher-fluorophore complex is formed. This is inferred from
the bimolecular quenching constant (Kq in equation 1) calculated by using τ0 = 22 ns [29]
for the EB-DNA complex. Kq for the reactions are on the order of 1012 M−1 s−1 which is
two orders of magnitude larger than the limiting value of 1010 M−1 s−1 [30] considered the
largest possible value in aqueous solution.
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In this equation KEB is the binding constant for ethidium bromide, taken as 1.2 × 106 M−1
[28] and [Ru]50% is the concentration of the complex that causes a 50% reduction of the
initial fluorescence. These values are shown in Table 1 and are on the order of 104 M−1
which again suggest that the complexes are moderate binders.

3.3.3 Viscometric studies—We have studied the interaction of the complexes with DNA
by viscometry. This method is the most definitive way to verify if a small molecule can bind
to DNA via an intercalative mechanism. The classical DNA intercalators will lengthen the
strands resulting in an increase in the viscosity of the DNA solutions. On the other hand,
complexes that bind exclusively in the DNA grooves by a partial or non-classical
intercalation of the compound, (under the same conditions), can reduce its effective length,
and consequently, its viscosity by bending the DNA helix [31]. The viscometric data,
presented as a plot of (η/η0)1/3 vs. the binding ratio [Ru]/[DNA], is shown in Figure 4. It was
observed for the complexes that the viscosity of the DNA solutions did not change
significantly over the studied range of metal concentrations. There is an overall slight
decrease in viscosity (with the exception of 3 which showed inconsistent changes). This
would suggest that the complexes can possibly interact with DNA via partial intercalation or
groove binding. It is well known that [Ru(bpy)3]2+ interacts with DNA strictly via
electrostatic interactions and since our complexes are charged, this mode of interaction is
also a possibility. Given the electronic nature of the piperonal sub-structure, major
intercalation into DNA by this moiety seems improbable. So the viscometry results support
the idea that if the complexes intercalate into DNA, the interaction is weak.
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3.3.4 Chemical nuclease activity—The chemical nuclease activity of complexes has
been assessed by their ability to convert supercoiled pBR322 DNA from Form I to Form II
by agarose gel electrophoresis in the dark as well as with UV irradiation under aerobic
conditions. When circular plasmid DNA is probed by electrophoresis, relatively fast
migration is normally observed for the intact supercoil form (Form I). If scission occurs on
one strand (nicking), the supercoil will relax to generate a slower-moving open circular form
(Form II). Figure 5, (see also Supplemental Information – S2), shows the electrophoretic
separation of the DNA after incubation with 1 in the dark and after irradiation. In general it
is clear that the complexes show some cleavage of the DNA and there is also a slight
increase in this activity as the concentration of the complexes is increased (up to 300 μM).
The extent of the cleavage is more pronounced when the reaction mixtures are irradiated
with UV light (365 nm). There are no apparent differences in the cleavage ability of the
complexes. This would suggest that the mechanism of cleavage is similar among the
complexes.
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3.3.5 Anti-topoisomerase activity—Though DNA is implicated as the main target for
anticancer ruthenium compounds, affecting the activity of topo II may also be an effective
mode of anti-neoplastic activity. Type II topoisomerases (topo II) are a class of ubiquitous
enzymes that modulate the topological problems associated with DNA replication,
transcription, and other nuclear processes by introducing temporary single- or double-strand
breaks in the DNA. Topo II is a major enzyme in neoplastic cells. Consequently
topoisomerases have been one of the major molecular targets in anticancer drug
development. The ability of the complexes to affect the catalytic activity of human
topoisomerases II was studied by a DNA relaxation assay. Supercoiled plasmid DNA was
treated with topo II in the presence of varying concentrations of the complex and the
products were analyzed by gel electrophoresis on agarose gel. Depending on the nature of
the products one can propose if the complex is a poison or an inhibitor. Topo II-targeting
agents control the topo II activity either by poisoning the enzyme or by inhibiting the
enzyme. Topo II poisons act by increasing the concentration of covalent enzyme-cleaved
DNA complexes. Catalytic inhibitors prevent topo II from carrying out its required
physiological functions. In our experiments (see Supplemental Information – S3) enzyme
activity is characterized by conversion of pHOT1 DNA from the supercoiled conformation
(SC, Form I, Lane 1) to the fully relaxed conformation (R, Form II; see lanes 2 and 3). The
species migrating between the two forms are the various topoisomers. Careful examination
of the electrophorograms suggests that the complexes can inhibit the relaxation of the
enzyme at high concentrations as evidenced by the reduction in the number of the
topoisomers but a fully relaxed conformation is not observed. So we propose that the
complexes can act as catalytic inhibitors of topo II.
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3.4 Antioxidant behavior
Based on the data from experiments that show that the complexes can bind to DNA and
further that there is strong activity regarding the cleavage of pBR322 plasmid DNA, we
investigated the antioxidant properties of the complexes by using the 2,2-diphenyl-1picrylhydrazyl (dpph) radical method. The model of the scavenging of dpph radicals is a
simple, rapid and convenient method that is extensively used to evaluate the antioxidant
properties of compounds. The dpph radicals are stable but in the presence of compounds
capable of donating hydrogen atoms the radical property is destroyed resulting in a color
change from purple to yellow. In our experiments we used ascorbic acid as a standard
comparison. It was observed that the complexes can indeed reduce the concentration of the
initial dpph radicals in solution and this is taken as evidence of their antioxidant capabilities.
All the compounds have similar IC50 values of 232 μM, 235 μM, 221 μM and 265 μM for 2,
3, 4 and 5 respectively. Under our reaction conditions ascorbic acid has an IC50 of 82 μM
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suggesting that our compounds are about three times less effective as the well-known
antioxidant under the reaction conditions. We can speculate that the cleavage of plasmid
DNA by the complexes may not involve the generation of radical species.
3.5 Reaction of the complexes with HSA
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Human serum albumin (HSA) is the most abundant blood serum protein, occurring to the
extent of 0.63 mM. The protein serves as a transport unit for a wide variety of endogenous
substances including drugs. In this study we investigated the binding of the complexes to
HSA using fluorescence spectroscopy. HSA has a well-known structure that contains a
single tryptophan residue that is responsible for the majority of the intrinsic fluorescence of
the protein. On excitation at 295 nm HSA has strong fluorescence emission at 350 nm. This
emission can be attenuated by a small molecule binding at or near the tryptophan as this
amino acid unit is quite susceptible to changes in its environment. As a representative
example, Figure 6 shows that addition of 2 to HSA can very efficiently reduce the
fluorescence so we can conclude that the complexes in general can bind to HSA. We can
obtain a quantitative estimate of the strength of this binding by treating the data in an
analogous manner to the EB-DNA competition experiments. That is, we can use the SternVolmer equation (Equation 1). Treatment of the data in this manner resulted in the plots
shown in Figure 7. It was observed that the plots were not linear as predicted from the
equation but showed significant positive deviations from linearity at higher concentration of
added metal complexes. There are two common explanations for this deviation. First the
HSA fluorescence can be quenched via both of the common quenching mechanisms
operating simultaneously. For proteins the quenching constants are approximately the same
[32, 33]. Alternatively, there may be more than one independent binding site on the HSA
and they are not all equivalently accessible to the complexes. Under these circumstances, the
binding constant for the reaction can be obtained from a modified Stern-Volmer (MSV)
analysis [34]. This involves treating the data using equation 3:

(3)
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Here f = fraction of the fluorophore that is initially accessible to the complex. This may be
interpreted as the number of binding sites on the protein. K is the effective quenching
constant for the fluorophore which can be taken as a binding constant assuming the decrease
in fluorescence comes from the interaction of the HSA with the complexes. Figure 8 shows
the plot of F0/F0-F vs. 1/[Ru] from which we obtain K from the ratio of the intercept to the
slope. The derived binding constants are between 104 and 105 M−1 (Table 2) indicating that
they are strong binders. The average number of binding sites as measured by f was
determined to be about 1.3. This number does not conclusively settle the question as to
whether there is a single binding site on the protein.
3.6 Cytotoxicity assay
The in vitro cytotoxicity of the complexes 1 – 5 against two human cancer cell lines,
HCT-116 (colon carcinoma) and Caco-2 (epithelial colorectal adenocarcinoma) and a noncancerous cell line, CCD-18Co (colon fibroblasts) was investigated using a tetrazoliumbased (MTS) colorimetric assay. Etoposide, a potent anti-neoplastic drug, was used as a
standard comparison treatment. The IC50 values (Table 3), the median cytotoxic
concentrations, were determined after 24, 48 and 72 h of drug exposure. Generally, the
longer the exposure time the more cytotoxic is the complexes with the 72 h exposure being
between 1.2 and 2 times more effective compared to the 24 h exposure. As another
generality, the Caco-2 cell line is slightly more sensitive to the complexes than the HCT-116
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cell line. For instance at 72 h exposure, 1 is 1.3 times as cytotoxic against the Caco-2 line.
We can speculate that the alkyl substituent on the thiosemicarbazone ligand is probably not
very critical. 4, which contain a methyl substituent on N3, is the most cytotoxic with IC50 of
8.6 and 6.6 μM at 72h exposure against HCT-116 and Caco-2 respectively. These values are
2 – 2.5 times as cytotoxic, under our assay conditions, as the comparison drug etoposide.
With the bpy complexes, the un-substituted (H) complex (1) is more active than the ethylsubstituted analog. On the other hand, for the phen complexes the ethyl-substituted complex
is more active. So we cannot draw any definitive conclusions as to any effect that the
diimine or the thiosemicarbazone substituent have on the cytotoxic behavior. An interesting
point to note is that all the complexes are less cytotoxic to the normal cells CCD18-Co
indicating a definite cytotoxic selectivity towards cancer cells. In the best case for 4 for
example, the compound is 17 times less cytotoxic to the normal cells. This effect is even
more pronounced than for the standard drug treatment with etoposide being only about ~2.5
times more lethal to the cancer cells versus the non-cancerous cells.
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The IC50 values for the complexes (Table 3) are in the range 7 – 159 μM after incubation for
72 h, indicating the good to poor cytotoxicity profiles of the complexes. Under the
experimental conditions 1 and 4 show comparable or better activity to etoposide against both
HCT-116 and Caco-2. In general however the complexes do not reach the activity of the
standard against the cancer cell lines. This is in itself not an unusual issue. It is known that
some ruthenium complexes have low in vitro toxicity but show good in vivo characteristics.
For example, complexes of the type [(arene)Ru(PTA)Cl]+ exhibited low activity against
cancer cells but had very good anti-metastatic activity in vivo [34].
3.7 Antibacterial assay
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The in vitro antimicrobial efficiency of the complexes against a number of Gram-positive
and Gram-negative bacteria has been determined as the minimum inhibitory concentrations.
The compounds were tested at low concentrations due to solubility issues and to avoid
excessive concentrations of the solvent DMSO in the wells. The complexes generally were
more active against the Gram-positive bacteria than the Gram-negative species. Complex 1
showed no inhibition against the four bacteria strains used: Bacillus cereus, Staphylococcus
aureus, Salmonella typhimurium or Escherichia coli. In addition 4 and 5 showed no
inhibition against B. cereus and S. aureus. Complex 2 showed very good activity against
both B. cereus and S. aureus with a MIC of 10 μM but it showed no inhibition against S.
typhimurium or E.coli 3 had an MIC of 20 μM against B. cereus, 30 μM against S. aureus
and 50 μM against E. coli. It did not show any activity against S. typhimurium. It should be
pointed out that no inhibition is relative only to the highest concentration (50 μM) of
complex that we used. We have studied the antibacterial activity of the free ligands as well
and in general the complexes were more active than the free ligands which showed no
measureable activity at the concentrations studied. This is not unusual as it is known that
complexation to a metal ion may induce improved biological activity [35] and in some cases
even different biological activity. Such complexation could enhance the lipophilic character
of the compound which favors its permeation through the lipid layers of cell membrane.

Conclusion
The complexes can bind to DNA in a nonspecific manner but the cytotoxic activity is not
definitively related to the strength of the binding. So we cannot rule out that the interaction
with DNA may contribute to the anticancer activity. We have also determined that human
topoisomerase II is a plausible molecular target for ruthenium complexes and we are
actively exploring this possibility in our laboratories. Since the complexes are strong binders
of human serum albumin, we are also investigating other model proteins to identify other
potential mechanisms for the anticancer activity of our ruthenium compounds.
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Fig. 1.

Structure of the ligands and complexes synthesized in the study.
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Fig. 2.

Fluorescence spectra of the EB-DNA complex in the absence and presence of increasing
amounts of 2, 1ex = 520 nm, [EB] = 0.33 mM, [DNA] = 10 mM, [2] (inM): 0 – 60 in 5 inM
increments. Temperature = 303 K.
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Fig. 3.

Stem-Volmer plots for the reaction of the complexes with EB-DNA at 308 K.
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Fig. 4.

Effect of increasing concentrations of complexes 1 ,2, 4 and 5 on the relative viscosity of ctDNA solutions at 304 K ± 1 K.
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Fig. 5.

Agarose gel electrophoresis diagram for the cleavage of pBR322 DNA by 1 at ambient
temperature in the dark (A) and upon irradiation with 365 nm light (B) under aerobic
conditions. Irradiation time was 1 h and incubation time was 1 h. Lane DNA, DNA alone;
Lane 1 –8, DNA + 10, 20, 30,40, 50,100, 200 and 300 mM 1; Lane 10, DNA ladder
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Fig. 6.
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Emission spectra of HSA in the absence and presence of increasing amounts of 2, 1ex = 295
nm, [HSA] = 5.0 nil and [2] (mM): 0–35 in 2.5 mM increments. Temperature = 303.0 K.
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Fig. 7.

Stem-Volmer plots for the reaction of the complexes with HSA at 308 K.
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Fig. 8.

Plot of the modified Stern-Volmer equation: F0/(F0 − F) vs. 1/[Ru], for the reaction of the
complexes with HSA.
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Beckford et al.
Page 23

J Mol Struct. Author manuscript; available in PMC 2012 April 19.

NIH-PA Author Manuscript
3.82 ± 0.11 (0.999)
-

298

303
9.35 ± 0.35 (0.992)

1.96 ± 0.49 (0.981)

293

308

1

Temperature (K)

9.10 ± 0.84 (0.986)

3.40 ± 0.06 (0.992)

-

-

2

5.10± 0.12 (0.999)

-

3.35± 0.31 (0.995)

3.61± 0.21 (0.993)

3

4

8.10± 0.76 (0.977)

-

6.60± 0.35 (0.992)

1.10± 0.21 (0.996)

104 K (M−1) (R2 beneath)
5

4.72± 0.05 (0.999)

-

-

1.45± 0.35 (0.992)
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Binding constants for the interaction of the complexes with HSA
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13.4 ± 3.1
56.1 ± 2.0

65.9 ± 2.9

27.2 ± 1.2

4

5

Etoposide

22.9 ± 1.5

67.4 ± 4.1

101 ± 6

17.8 ± 2.5

3

174 ± 6

32.4 ± 3.3

48 h

198 ± 4

36.9 ± 4.9

24 h

HCT-116

2

1

Comp.

18.3 ± 1.4

42.6 ± 3.7

8.6 ± 2.1

55.6 ± 3.6

159 ± 4

27.5 ± 3.3

72 h

23.1 ± 1.2

65.9 ± 3.8

19.5 ± 2.8

97.0 ± 6.4

148 ± 3

39.2 ± 4.0

24 h

48 h

Caco-2

17.9 ± 1.3

56.2 ± 1.9

15.2 ± 3.7

76.4 ± 4.0

138 ± 3

31.0 ± 4.4

IC50

16.5 ± 2.0

36.8 ± 2.8

6.6 ± 2.4

58.9 ± 4.1

130 ± 3

22.2 ± 4.7

72 h

50.1 ± 1.5

181 ± 4

212 ± 6

221 ± 6

nd

220 ± 6

24 h

45.2 ± 1.1

136 ± 2

136 ± 3

179 ± 5

321 ± 5

153 ± 4

48 h

CCD-18Co

42.2 ± 1.0

127 ± 2

114 ± 2

167 ± 4

304 ± 4

145 ± 3

72 h

IC50 values (μM) representing the anti-proliferative activity of all the complexes in a panel of three human cell lines – 2 tumorigenic (HCT-116 and
Caco-2) and one non-cancerous (CCD-18Co).
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